ALLR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
25.0K
-92.2%
320.0K
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
25.0K
-92.2%
320.0K
0
0
Operating Expenses
2.7M
-1.5%
2.7M
-16.2%
3.2M
+28.6%
2.5M
-39.1%
4.1M
R&D
1.3M
+3.7%
1.3M
-22.5%
1.7M
+39.2%
1.2M
-48.2%
2.3M
SG&A
1.3M
-6.4%
1.4M
-9.5%
1.6M
+18.9%
1.3M
-27.4%
1.8M
Operating Income
-2671000
+0.6%
-2688000
+7.9%
-2918000
-15.9%
-2518000
+39.1%
-4133000
EBITDA
-2637000
+2.8%
-2714000
+6.7%
-2910000
-13.6%
-2562000
+37.8%
-4121000
Net Income
-3405000
-23.8%
-2750000
+18.5%
-3373000
-20.2%
-2806000
-20.9%
-2320000
EPS (Basic)
$-0.21
-23.5%
$-0.17
+19.0%
$-0.21
-10.5%
$-0.19
-26.7%
$-0.15
EPS (Diluted)
$-0.21
-23.5%
$-0.17
+19.0%
$-0.21
-10.5%
$-0.19
-26.7%
$-0.15
Shares (Diluted)
15.9M
-0.4%
16.0M
-0.7%
16.1M
+9.1%
14.7M
-5.2%
15.5M
Allarity Therapeutics (ALLR) โ€” Financials